24 April 2024
24 April 2024
As awareness surrounding social prescribing grows, can this initiative go hand in hand with the pharmaceutical industry?
The legal battle between the entities extends beyond the UK.
The future of Hepion’s ASCEND-NASH study was already in the balance following cost-cutting measures last December.
Tislelizumab is greenlit as a first-line treatment in combination with certain drugs for non-small cell lung cancer.
At the Swiss Biotech Day conference, key opinion leaders discussed trends in pharmaceutical partnerships.
At the Swiss Biotech Day Conference, key opinion leaders discussed ways to reduce disparities caused by reduced regulatory capacities.
LightOx explained how light-activated drugs can be used to treat cancer on day one of the BioTrinity 2024 conference in London.
Sanofi’s rilzabrutinib met the primary endpoint in the Phase III persistent or chronic immune thrombocytopenia trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
